我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
招募中
100.0%
暂无批准数据
- Algernon NeuroScience appoints Dr. Sándor Nardai to lead a groundbreaking Phase 2a clinical trial investigating DMT as a potential stroke recovery treatment, set to begin in Q3 2025. - The 40-patient randomized trial will evaluate DMT's safety profile and monitor key indicators including lesion volume, motor function, and cognitive improvements in stroke patients. - Preclinical studies showed promising results with sub-hallucinogenic DMT doses, demonstrating near-complete motor function recovery and reduced infarct volumes in rat models.
